CLINICAL TRIALS PROFILE FOR INGREZZA
✉ Email this page to a colleague
All Clinical Trials for ingrezza
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03325010 ↗ | Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome | Completed | Neurocrine Biosciences | Phase 2 | 2017-10-05 | This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-optimization study to evaluate the efficacy, safety, and tolerability of NBI-98854 titrated to the subject's optimal dose administered once daily (qd) for a total of 12 weeks of treatment in pediatric subjects with TS. |
NCT03444038 ↗ | Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome | Completed | Neurocrine Biosciences | Phase 2 | 2018-02-08 | This is a Phase 2b, multicenter, open-label study to evaluate the safety and tolerability of optimized doses of NBI-98854 administered once daily for 24 weeks in pediatric subjects with Tourette Syndrome. |
NCT03530293 ↗ | Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome | Terminated | Neurocrine Biosciences | Phase 2 | 2018-04-16 | This is a Phase 2, double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety and maintenance of efficacy of an optimized once-daily (qd) dose of NBI-98854 in pediatric subjects with TS. |
NCT03732534 ↗ | Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome | Terminated | Neurocrine Biosciences | Phase 2 | 2018-10-17 | This is an open-label, rollover study to collect long-term safety, tolerability, and investigator- and participant-reported pharmacodynamic (PD) data after chronic administration of NBI-98854 in pediatric participants with Tourette Syndrome (TS), as well as to provide open-label access to NBI-98854 for the treatment of TS for pediatric participants who have taken part in a Phase 2 NBI-98854 study. |
NCT05157100 ↗ | Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia | Enrolling by invitation | The Orthopedic Foundation | Phase 4 | 2021-10-19 | STUDY OF INGREZZA (VALBENAZINE) FOR THE TREATMENT OF CERVICAL DYSTONIA |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ingrezza
Condition Name
Clinical Trial Locations for ingrezza
Trials by Country
Clinical Trial Progress for ingrezza
Clinical Trial Phase
Clinical Trial Sponsors for ingrezza
Sponsor Name